Pancreatic Adenocarcinoma Clinical Trials

A listing of 31 Pancreatic Adenocarcinoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Pancreatic Adenocarcinoma

13 - 24 of 31

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 31 active clinical trials seeking participants for Pancreatic Adenocarcinoma research studies. The states with the highest number of trials for Pancreatic Adenocarcinoma participants are California, Ohio, Michigan and Illinois.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

NCT05877599

Recruiting

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: City of Hope, Duarte, California +8 locations

Conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer

Learn More ›

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

NCT05585320

Recruiting

This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: Mayo Clinic, Scottsdale, Arizona +19 locations

Conditions: Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor

Learn More ›

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

NCT05365581

Recruiting

Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein called on a type of immune cell called a T-cell. This "tells" the immune system to attack the tumor. ASP2138 is a potential treatment for people with stomach cancer, gastroesophageal junction cancer, (GEJ cancer) or pancreatic cancer. GEJ is where the tube that carries food (esophagus) joins the stomach). Before ASP2138 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. In this study, ASP2138 will either be given by itself, or given together with standard treatments for gastric, GEJ and pancreatic cancer. Pembrolizumab and mFOLFOX6 (modified leucovorin \[folinic acid\], 5-FU \[fluorouracil\], and oxaliplatin), and ramucirumab and paclitaxel are standard treatments for gastric and GEJ cancer. mFOLFIRINOX (modified leucovorin \[folinic acid\], 5-FU \[fluorouracil\], irinotecan and oxaliplatin) is a standard treatment for pancreatic cancer. This information will help to find a suitable dose of ASP2138 given by itself and together with the standard cancer treatments and to check for potential medical problems from the treatments. Adults 18 years or older with stomach cancer, GEJ cancer, or pancreatic cancer can take part. Their cancer is locally advanced unresectable or metastatic. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. The main aims of the study are to check the safety of ASP2138, and how well people cope with (tolerate) any medical problems during the study, and to find a suitable dose of ASP2138 to be used later in this study. These are done for ASP2138 given by itself and when given together with the standard cancer treatments. The study will have 2 phases. In phase 1, different small groups of people will receive lower to higher doses of ASP2138 given by itself or together with the standard cancer treatments. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP2138 to use later in the study. Doctors will also check how each type of cancer responds to ASP2138. In phase 1b, other different small groups will receive suitable doses of ASP2138 given by itself or together with the standard cancer treatments. Suitable doses will be found from phase 1. Phase 1b will check how each type of cancer responds to ASP2138 given by itself or together with the standard cancer treatments. The response to ASP2138 is measured using scans and blood tests. Safety checks will be done at each visit and the doctors will continue to check for all medical problems throughout the study. ASP2138 will be given either through a vein (intravenous infusion) or just below the skin (subcutaneous injection). Treatment will be in a 14-day cycle (2 weeks). In each treatment cycle, intravenous infusions or subcutaneous injections will either be given once a week or once every 2 weeks. People will continue to receive treatment until their cancer gets worse or the doctor decides to stop the person's treatment. People will visit the clinic on certain days during their treatment, with extra visits during the first 3 cycles of treatment. After treatment has finished, people will visit the clinic for a health check several times. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their treatment or not. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/17/2025

Locations: University of California Irvine Medical Center, Orange, California +38 locations

University of California Irvine Medical Center, Orange, California

UCLA Dept of Medicine - Hematology/Oncology, Santa Monica, Santa Monica, California

Northwestern University, Chicago, Illinois

University of Kansas Cancer Center, Westwood, Kansas

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

NYU Langone Medical Center - NYU Medical Oncology Associates, New York, New York

Columbia University, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Duke Children's Hospital and Health Center, Durham, North Carolina

Wake Forest University Baptist Health, Winston-Salem, North Carolina

UT Southwestern Medical Center, Dallas, Texas

Virginia Mason Medical Center, Seattle, Washington

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

Henan Cancer Hospital, Zhengzhou, Henan

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang

Site FR33005, Vaillant, Villejuif

Site FR33003, Lyon Cedex 08, Not set

Site FR33004, Marseille, Not set

Site FR33001, Saint-Herblain, Not set

Site FR33002, Toulouse, Not set

Site IT39001, Milano, Not set

Site IT39004, Milan, Not set

Site IT39005, Rozzano, Not set

Site IT39003, Verona, Not set

Aichi Cancer Center, Nagoya, Aichi

National Cancer Center Hospital East, Kashiwa, Chiba

Kanagawa Cancer Center, Yokohama, Kanagawa

Kindai University Hospital, Osakasayama, Osaka

Osaka University Hospital, Suita, Osaka

National Cancer Center Hospital, Chuo-ku, Tokyo

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo

Site KR82004, Seongnam-si, Gyeonggi-do

Site KR82001, Guro-gu, Seoul

Site KR82002, Jongno-gu, Seoul

Site KR82003, Seocho-gu, Seoul

Site KR82005, Seodaemun-gu, Seoul

Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma

Learn More ›

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

NCT06399757

Recruiting

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/14/2025

Locations: City of Hope, Duarte, California +8 locations

Conditions: Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer

Learn More ›

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

NCT03384238

Recruiting

This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to see how well it works in finding cancer in patients with pancreatic cancer who are undergoing surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with pancreatic cancer.

Gender:

ALL

Ages:

19 years and above

Trial Updated:

02/14/2025

Locations: Stanford University, School of Medicine, Palo Alto, California

Conditions: Pancreatic Adenocarcinoma

Learn More ›

Evaluating Novel Therapies in ctDNA Positive GI Cancers

NCT05482516

Recruiting

This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocarcinomas) diagnosed with histologically confirmed GI cancers. These patients will have already completed all Standard of Care (SOC) treatments (including neoadjuvant, surgery, local therapies, and/or adjuvant therapy as applicable), as defined by the treating pr... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/12/2025

Locations: Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia +2 locations

Conditions: Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma

Learn More ›

Study of DECOY20 with or Without Tislelizumab in Patients with Advanced Solid Tumors

NCT05651022

Recruiting

INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/07/2025

Locations: University of Southern California- Norris Cancer Center, Los Angeles, California +9 locations

Conditions: Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer

Learn More ›

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

NCT03740256

Recruiting

This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to h... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/05/2025

Locations: Baylor St. Luke's Medical Center, Houston, Texas

Conditions: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor

Learn More ›

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

NCT01365169

Recruiting

The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and overall survival. The purpose is to advance the evidence-base for incorporating objective assessment of Physical Activity (PA) in the context of performance status assessment in advanced cancer patients.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix, Pancreatic Adenocarcinoma, Pancreatic Neuroendocrine Carcinoma, Recurrent Colorectal Carcinoma, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Hypopharyngeal Carcinoma AJCC v7, Stage I Major Salivary Gland Cancer AJCC v7, Stage I Nasopharyngeal Carcinoma AJCC v7, Stage I Oral Cavity Cancer AJCC v6 and v7, Stage I Oropharyngeal Carcinoma AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Hypopharyngeal Carcinoma AJCC v6 and v7, Stage II Major Salivary Gland Cancer AJCC v7, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage II Oral Cavity Cancer AJCC v6 and v7, Stage II Oropharyngeal Carcinoma AJCC v6 and v7, Stage IIA Colorectal Cancer AJCC v7, Stage IIB Colorectal Cancer AJCC v7, Stage IIC Colorectal Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Hypopharyngeal Carcinoma AJCC v7, Stage III Laryngeal Cancer AJCC v6 and v7, Stage III Major Salivary Gland Cancer AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Oral Cavity Cancer AJCC v6 and v7, Stage III Oropharyngeal Carcinoma AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVA Hypopharyngeal Carcinoma AJCC v7, Stage IVA Laryngeal Cancer AJCC v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Carcinoma AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Stage IVB Hypopharyngeal Carcinoma AJCC v7, Stage IVB Laryngeal Cancer AJCC v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Carcinoma AJCC v7, Metastatic or Locally Unresectable Solid Tumor

Learn More ›

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

NCT06115499

Recruiting

This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with pancreatic cancer that has spread to other places in the body (metastatic) and a known genetic mutation in the BRCA1, BRCA2, or PALB2 gene.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/09/2025

Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +277 locations

Anchorage Associates in Radiation Medicine, Anchorage, Alaska

Anchorage Radiation Therapy Center, Anchorage, Alaska

Alaska Breast Care and Surgery LLC, Anchorage, Alaska

Alaska Oncology and Hematology LLC, Anchorage, Alaska

Alaska Women's Cancer Care, Anchorage, Alaska

Anchorage Oncology Centre, Anchorage, Alaska

Katmai Oncology Group, Anchorage, Alaska

Providence Alaska Medical Center, Anchorage, Alaska

CTCA at Western Regional Medical Center, Goodyear, Arizona

Cancer Center at Saint Joseph's, Phoenix, Arizona

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas

Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California

Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California

Mercy Cancer Center - Carmichael, Carmichael, California

Mercy San Juan Medical Center, Carmichael, California

Mercy Cancer Center - Elk Grove, Elk Grove, California

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California

UCI Health Laguna Hills, Laguna Hills, California

Mercy Cancer Center, Merced, California

Providence Queen of The Valley, Napa, California

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California

Mercy Cancer Center - Rocklin, Rocklin, California

Mercy Cancer Center - Sacramento, Sacramento, California

UCSF Medical Center-Mission Bay, San Francisco, California

Pacific Central Coast Health Center-San Luis Obispo, San Luis Obispo, California

Mission Hope Medical Oncology - Santa Maria, Santa Maria, California

Providence Medical Foundation - Santa Rosa, Santa Rosa, California

Providence Santa Rosa Memorial Hospital, Santa Rosa, California

Woodland Memorial Hospital, Woodland, California

Penrose-Saint Francis Healthcare, Colorado Springs, Colorado

Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado

Saint Francis Cancer Center, Colorado Springs, Colorado

Mercy Medical Center, Durango, Colorado

Southwest Oncology PC, Durango, Colorado

Saint Anthony Hospital, Lakewood, Colorado

Longmont United Hospital, Longmont, Colorado

Saint Mary Corwin Medical Center, Pueblo, Colorado

Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida

Mount Sinai Medical Center, Miami Beach, Florida

Hawaii Cancer Care - Westridge, Aiea, Hawaii

Pali Momi Medical Center, Aiea, Hawaii

Queen's Cancer Center - Pearlridge, Aiea, Hawaii

The Cancer Center of Hawaii-Pali Momi, Aiea, Hawaii

The Queen's Medical Center - West Oahu, Ewa Beach, Hawaii

Hawaii Cancer Care Inc - Waterfront Plaza, Honolulu, Hawaii

Queen's Cancer Cenrer - POB I, Honolulu, Hawaii

Queen's Medical Center, Honolulu, Hawaii

Straub Clinic and Hospital, Honolulu, Hawaii

University of Hawaii Cancer Center, Honolulu, Hawaii

Hawaii Diagnostic Radiology Services LLC, Honolulu, Hawaii

Kuakini Medical Center, Honolulu, Hawaii

Queen's Cancer Center - Kuakini, Honolulu, Hawaii

The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii

Kapiolani Medical Center for Women and Children, Honolulu, Hawaii

Straub Medical Center - Kahului Clinic, Kahului, Hawaii

Castle Medical Center, Kailua, Hawaii

Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii

Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho

Kootenai Health - Coeur d'Alene, Coeur D'Alene, Idaho

Walter Knox Memorial Hospital, Emmett, Idaho

Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho

Idaho Urologic Institute-Meridian, Meridian, Idaho

Saint Luke's Cancer Institute - Meridian, Meridian, Idaho

Saint Alphonsus Cancer Care Center-Nampa, Nampa, Idaho

Saint Luke's Cancer Institute - Nampa, Nampa, Idaho

Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho

Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho

Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho

Rush - Copley Medical Center, Aurora, Illinois

Illinois CancerCare-Bloomington, Bloomington, Illinois

Illinois CancerCare-Canton, Canton, Illinois

Memorial Hospital of Carbondale, Carbondale, Illinois

SIH Cancer Institute, Carterville, Illinois

Illinois CancerCare-Carthage, Carthage, Illinois

Centralia Oncology Clinic, Centralia, Illinois

University of Illinois, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Carle at The Riverfront, Danville, Illinois

Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Illinois CancerCare-Dixon, Dixon, Illinois

Carle Physician Group-Effingham, Effingham, Illinois

Crossroads Cancer Center, Effingham, Illinois

Illinois CancerCare-Eureka, Eureka, Illinois

Illinois CancerCare-Galesburg, Galesburg, Illinois

Western Illinois Cancer Treatment Center, Galesburg, Illinois

Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois

Illinois CancerCare-Macomb, Macomb, Illinois

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois

UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois

Cancer Care Center of O'Fallon, O'Fallon, Illinois

HSHS Saint Elizabeth's Hospital, O'Fallon, Illinois

University of Chicago Medicine-Orland Park, Orland Park, Illinois

Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois

Illinois CancerCare-Pekin, Pekin, Illinois

Illinois CancerCare-Peoria, Peoria, Illinois

Methodist Medical Center of Illinois, Peoria, Illinois

Illinois CancerCare-Peru, Peru, Illinois

Valley Radiation Oncology, Peru, Illinois

Illinois CancerCare-Princeton, Princeton, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Springfield Clinic, Springfield, Illinois

Springfield Memorial Hospital, Springfield, Illinois

Carle Cancer Center, Urbana, Illinois

Illinois CancerCare - Washington, Washington, Illinois

Rush-Copley Healthcare Center, Yorkville, Illinois

Northwest Cancer Center - Main Campus, Crown Point, Indiana

Northwest Oncology LLC, Dyer, Indiana

Northwest Cancer Center - Hobart, Hobart, Indiana

Saint Mary Medical Center, Hobart, Indiana

Saint Catherine Hospital, Indianapolis, Indiana

The Community Hospital, Munster, Indiana

Women's Diagnostic Center - Munster, Munster, Indiana

Northwest Cancer Center - Valparaiso, Valparaiso, Indiana

Mary Greeley Medical Center, Ames, Iowa

McFarland Clinic - Ames, Ames, Iowa

Mission Cancer and Blood - Ankeny, Ankeny, Iowa

McFarland Clinic - Boone, Boone, Iowa

Mercy Hospital, Cedar Rapids, Iowa

Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa

Mercy Cancer Center-West Lakes, Clive, Iowa

Mission Cancer and Blood - West Des Moines, Clive, Iowa

Alegent Health Mercy Hospital, Council Bluffs, Iowa

Heartland Oncology and Hematology LLP, Council Bluffs, Iowa

Methodist Jennie Edmundson Hospital, Council Bluffs, Iowa

Greater Regional Medical Center, Creston, Iowa

Iowa Methodist Medical Center, Des Moines, Iowa

Mission Cancer and Blood - Des Moines, Des Moines, Iowa

Mercy Medical Center - Des Moines, Des Moines, Iowa

Mission Cancer and Blood - Laurel, Des Moines, Iowa

McFarland Clinic - Trinity Cancer Center, Fort Dodge, Iowa

McFarland Clinic - Jefferson, Jefferson, Iowa

McFarland Clinic - Marshalltown, Marshalltown, Iowa

Mercy Medical Center-West Lakes, West Des Moines, Iowa

Flaget Memorial Hospital, Bardstown, Kentucky

Commonwealth Cancer Center-Corbin, Corbin, Kentucky

Saint Joseph Hospital, Lexington, Kentucky

Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky

Saint Joseph Hospital East, Lexington, Kentucky

Saint Joseph London, London, Kentucky

Saint Joseph Mount Sterling, Mount Sterling, Kentucky

Hickman Cancer Center, Adrian, Michigan

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Bronson Battle Creek, Battle Creek, Michigan

University of Michigan - Brighton Center for Specialty Care, Brighton, Michigan

Henry Ford Hospital, Detroit, Michigan

Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan

Trinity Health Grand Rapids Hospital, Grand Rapids, Michigan

Bronson Methodist Hospital, Kalamazoo, Michigan

West Michigan Cancer Center, Kalamazoo, Michigan

Ascension Borgess Cancer Center, Kalamazoo, Michigan

Ascension Borgess Hospital, Kalamazoo, Michigan

Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan

Trinity Health Muskegon Hospital, Muskegon, Michigan

Corewell Health Lakeland Hospitals - Niles Hospital, Niles, Michigan

Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan

Corewell Health Reed City Hospital, Reed City, Michigan

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center, Saint Joseph, Michigan

Corewell Health Lakeland Hospitals - Saint Joseph Hospital, Saint Joseph, Michigan

Munson Medical Center, Traverse City, Michigan

University of Michigan Health - West, Wyoming, Michigan

Minnesota Oncology - Burnsville, Burnsville, Minnesota

Cambridge Medical Center, Cambridge, Minnesota

Mercy Hospital, Coon Rapids, Minnesota

Fairview Southdale Hospital, Edina, Minnesota

Fairview Clinics and Surgery Center Maple Grove, Maple Grove, Minnesota

Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota

Saint John's Hospital - Healtheast, Maplewood, Minnesota

Abbott-Northwestern Hospital, Minneapolis, Minnesota

Hennepin County Medical Center, Minneapolis, Minnesota

Health Partners Inc, Minneapolis, Minnesota

Monticello Cancer Center, Monticello, Minnesota

New Ulm Medical Center, New Ulm, Minnesota

Fairview Northland Medical Center, Princeton, Minnesota

North Memorial Medical Health Center, Robbinsdale, Minnesota

Coborn Cancer Center at Saint Cloud Hospital, Saint Cloud, Minnesota

Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota

Regions Hospital, Saint Paul, Minnesota

United Hospital, Saint Paul, Minnesota

Saint Francis Regional Medical Center, Shakopee, Minnesota

Lakeview Hospital, Stillwater, Minnesota

Ridgeview Medical Center, Waconia, Minnesota

Rice Memorial Hospital, Willmar, Minnesota

Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota

Fairview Lakes Medical Center, Wyoming, Minnesota

Baptist Memorial Hospital and Cancer Center-Golden Triangle, Columbus, Mississippi

Baptist Cancer Center-Grenada, Grenada, Mississippi

Baptist Memorial Hospital and Cancer Center-Union County, New Albany, Mississippi

Baptist Memorial Hospital and Cancer Center-Oxford, Oxford, Mississippi

Baptist Memorial Hospital and Cancer Center-Desoto, Southhaven, Mississippi

Saint Francis Medical Center, Cape Girardeau, Missouri

Southeast Cancer Center, Cape Girardeau, Missouri

Parkland Health Center - Farmington, Farmington, Missouri

Missouri Baptist Medical Center, Saint Louis, Missouri

Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri

Missouri Baptist Sullivan Hospital, Sullivan, Missouri

BJC Outpatient Center at Sunset Hills, Sunset Hills, Missouri

Community Hospital of Anaconda, Anaconda, Montana

Billings Clinic Cancer Center, Billings, Montana

Bozeman Health Deaconess Hospital, Bozeman, Montana

Benefis Sletten Cancer Institute, Great Falls, Montana

Great Falls Clinic, Great Falls, Montana

Hi-Line Sletten Cancer Center, Havre, Montana

Logan Health Medical Center, Kalispell, Montana

Saint Patrick Hospital - Community Hospital, Missoula, Montana

Community Medical Center, Missoula, Montana

CHI Health Good Samaritan, Kearney, Nebraska

Saint Elizabeth Regional Medical Center, Lincoln, Nebraska

Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha, Nebraska

Nebraska Methodist Hospital, Omaha, Nebraska

Oncology Associates PC, Omaha, Nebraska

Alegent Health Immanuel Medical Center, Omaha, Nebraska

Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska

Alegent Health Lakeside Hospital, Omaha, Nebraska

Creighton University Medical Center, Omaha, Nebraska

Midlands Community Hospital, Papillion, Nebraska

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire

Dartmouth Cancer Center - Nashua, Nashua, New Hampshire

University of New Mexico Cancer Center, Albuquerque, New Mexico

Glens Falls Hospital, Glens Falls, New York

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Oklahoma Cancer Specialists and Research Institute-Tulsa, Tulsa, Oklahoma

Saint Alphonsus Cancer Care Center-Baker City, Baker City, Oregon

Saint Charles Health System, Bend, Oregon

Clackamas Radiation Oncology Center, Clackamas, Oregon

Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon

Bay Area Hospital, Coos Bay, Oregon

Providence Newberg Medical Center, Newberg, Oregon

Saint Alphonsus Cancer Care Center-Ontario, Ontario, Oregon

Providence Willamette Falls Medical Center, Oregon City, Oregon

Providence Portland Medical Center, Portland, Oregon

Providence Saint Vincent Medical Center, Portland, Oregon

Saint Charles Health System-Redmond, Redmond, Oregon

Baptist Memorial Hospital and Cancer Center-Collierville, Collierville, Tennessee

Baptist Memorial Hospital and Cancer Center-Memphis, Memphis, Tennessee

Parkland Memorial Hospital, Dallas, Texas

UT Southwestern Simmons Cancer Center - RedBird, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth, Texas

UT Southwestern Clinical Center at Richardson/Plano, Richardson, Texas

Dartmouth Cancer Center - North, Saint Johnsbury, Vermont

Providence Regional Cancer System-Aberdeen, Aberdeen, Washington

PeaceHealth Saint Joseph Medical Center, Bellingham, Washington

Providence Regional Cancer System-Centralia, Centralia, Washington

Swedish Cancer Institute-Edmonds, Edmonds, Washington

Providence Regional Cancer Partnership, Everett, Washington

Swedish Cancer Institute-Issaquah, Issaquah, Washington

Kadlec Clinic Hematology and Oncology, Kennewick, Washington

Providence Regional Cancer System-Lacey, Lacey, Washington

PeaceHealth Saint John Medical Center, Longview, Washington

Skagit Regional Health Cancer Care Center, Mount Vernon, Washington

Swedish Medical Center-Ballard Campus, Seattle, Washington

Swedish Medical Center-Cherry Hill, Seattle, Washington

Swedish Medical Center-First Hill, Seattle, Washington

PeaceHealth United General Medical Center, Sedro-Woolley, Washington

Providence Regional Cancer System-Shelton, Shelton, Washington

Saint Michael Cancer Center, Silverdale, Washington

PeaceHealth Southwest Medical Center, Vancouver, Washington

Providence Saint Mary Regional Cancer Center, Walla Walla, Washington

Providence Regional Cancer System-Yelm, Yelm, Washington

Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin

Marshfield Medical Center - Minocqua, Minocqua, Wisconsin

Cancer Center of Western Wisconsin, New Richmond, Wisconsin

Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin

Marshfield Medical Center-River Region at Stevens Point, Stevens Point, Wisconsin

Marshfield Medical Center - Weston, Weston, Wisconsin

Billings Clinic-Cody, Cody, Wyoming

Welch Cancer Center, Sheridan, Wyoming

Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC v8

Learn More ›

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

NCT04895709

Recruiting

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/03/2025

Locations: Community Cancer Institute, Clovis, California +46 locations

Community Cancer Institute, Clovis, California

USC/Norris Comprehensive Cancer Center, Los Angeles, California

Hoag Memorial Hospital Presbyterian, Newport Beach, California

University of Iowa, Iowa City, Iowa

John Theurer Cancer Center, Hackensack, New Jersey

Columbia University Irving Medical Center, New York, New York

Local Institution - 0002, New York, New York

Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon

Local Institution - 0063, Nashville, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Houston Methodist Hospital, Houston, Texas

Blacktown Hospital, Blacktown, New South Wales

Liverpool Hospital, Liverpool, New South Wales

Princess Alexandra Hospital, Brisbane, Queensland

Cabrini Hospital - Malvern, Malvern, Victoria

St Vincent's Hospital, Melbourne, Victoria

One Clinical Research, Nedlands, Western Australia

Cross Cancer Institute, Edmonton, Alberta

BC Cancer Vancouver, Vancouver, British Columbia

Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario

Local Institution - 0009, Toronto, Ontario

Centre Hospitalier de luniversite de Montreal, Montreal, Quebec

The Ottawa Hospital Cancer Centre, Ottawa, Not set

Universitaetsklinikum Ulm, Ulm, Baden-Wurttemberg

Universitaetsklinikum Carl Gustav Carus Dresden-University Cancer Center Early Clinical Trial Unit, Dresden, Not set

Universitaetsklinikum Essen, Essen, Not set

Universitatsklinikum Frankfurt, Frankfurt, Not set

Universitaetsklinikum Wuerzburg, Wuerzburg, Not set

Rabin Medical Center, Petah Tikva, HaMerkaz

Local Institution - 0035, Ramat Gan, HaMerkaz

Sheba Medical Center, Ramat Gan, HaMerkaz

Rambam Health Care Campus, Haifa, HaTsafon

Sourasky Medical Center, Tel Aviv, Tell Abīb

Humanitas, Rozzano, Milano

Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia, Candiolo, Torino

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1, Milan, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS Universita Cattolica del Sacro Cuore, Roma, Not set

ospedale le scotte-U.O.C. Immunoterapia Oncologica, Siena, Not set

National Cancer Center Hospital East, Kashiwa, Chiba

Hospital Universitario Virgen de la Victoria, Málaga, Andalucía

Institut Catalan d Oncologia (ICO) - Badalona, Badalona, Barcelona [Barcelona]

Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona]

Hospital Universitario 12 de Octubre, Madrid, Madrid, Comunidad De

Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD, Madrid, Not set

Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid-CIOCC, Madrid, Not set

Clinica Universidad de Navarra-oNCOLOGY, Pamplona, Not set

Conditions: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Learn More ›

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444

Recruiting

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/04/2024

Locations: University of Alabama at Birmingham, Birmingham, Alabama +56 locations

University of Alabama at Birmingham, Birmingham, Alabama

Ironwood Cancer & Research Centers, Chandler, Arizona

Genesis Cancer Center, Hot Springs, Arkansas

University of California, San Diego, La Jolla, California

Hoag Memorial Hospital Presbyterian, Newport Beach, California

Redwood City, Redwood City, California

Sutter Institute for Medical Research, Sacramento, California

University of Colorado, Aurora, Colorado

Memorial Healthcare System, Hollywood, Florida

The Oncology Institute of Hope & Innovation, Lakeland, Florida

Tulane Cancer Center, New Orleans, Louisiana

Christus Highland/ Boniol, Shreveport, Louisiana

Central Maine Medical Center, Lewiston, Maine

Massachusetts General Hospital, Boston, Massachusetts

Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan

Mayo Clinic (Rochester), Rochester, Minnesota

Astera Cancer Care, East Brunswick, New Jersey

Icahn School of Medicine at Mount Sinai, New York, New York

UNC- Chapel Hill, Chapel Hill, North Carolina

The Christ Hospital Cancer Center, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

Toledo Clinic Cancer Center, Toledo, Ohio

Crozer-Keystone Health System, Broomall, Pennsylvania

University of Pennsylvania, Philadelphia, Pennsylvania

Cancer Care Associates of York, York, Pennsylvania

Carolina Urologic Research Center, Myrtle Beach, South Carolina

Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina

UT Southwestern Medical Center, Dallas, Texas

DHR Health Advance Care Center, Edinburg, Texas

The Center for Cancer and Blood Disorders, Fort Worth, Texas

The University of Texas Health Science Center at San Antonio, San Antonio, Texas

Utah Cancer Specialists, Salt Lake City, Utah

ThedaCare Regional Cancer Center, Appleton, Wisconsin

CHU Besançon, Besançon, Not set

Hôpital Franco-Britannique, Levallois-Perret, Not set

Institut Paoli-Calmettes, Marseille, Not set

Ambroise Paré-Hartmann, Neuilly, Not set

APHP Tenon Hospital - Sorbonne, Paris, Not set

Asklepios Klinik Altona, Hamburg, Not set

SLK-Kliniken Heilbronn GmbH, Heilbronn, Not set

Ludwig Maximilian University Munich, Munich, Not set

Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori" IRCCS IRST, SrL, Meldola, Not set

Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Not set

Policlinico Universitario Agostino Gemelli, Roma, Not set

Hospital Teresa Herrera (C.H.U.A.C), A Coruña, Not set

Vall Hebron Institute of Oncology, Barcelona, Not set

Hospital Clinic of Barcelona, Barcelona, Not set

ICO Institut Catala d'Oncologia, Barcelona, Not set

Instituto Catalan de Oncologia de Girona, Girona, Not set

Hospital Universitario Insular de Gran Canaria, Las Palmas De Gran Canaria, Not set

Hospital San Carlos, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

CIOSS HM Sanchinarro, Madrid, Not set

Hospital Universitario Virgen de la Victoria, Málaga, Not set

CCS Hospital Universitari Parc Taulí, Sabadell, Not set

Hospital Clinico de Santiago de Compostela, Santiago De Compostela, Not set

Hospital Clínico de Valencia, Valencia, Not set

Conditions: Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma

Learn More ›

13 - 24 of 31